Abstracts Archive - Page 1398 of 2607 - ACR Meeting Abstracts

Abstract Number: 160 • 2017 ACR/ARHP Annual Meeting
Fibromyalgia Screening Form in the Diagnosis of Concomitant Fibromyalgia
Robert S. Katz¹ and Jessica L. Polyak², ¹Rush University Medical Center, Chicago, IL, ²Rheumatology Associates S.C., Chicago, IL
Background/Purpose: We have found that patients with a variety of rheumatic diseases who have concomitant fibromyalgia more frequently fail therapies for the underlying inflammatory rheumatic…
Abstract Number: 161 • 2017 ACR/ARHP Annual Meeting
The Effectiveness of Medications for Fibromyalgia Based on Patient Experiences
Robert S. Katz and Frank Leavitt, Rush University Medical Center, Chicago, IL
Background/Purpose: To assess patients’ global assessment of frequently used treatments for the fibromyalgia syndrome (FMS), we asked patients with fibromyalgia to rank medications they have…
Abstract Number: 162 • 2017 ACR/ARHP Annual Meeting
Depression Versus Frustration
Robert S. Katz¹ and Jessica L. Polyak², ¹Rush University Medical Center, Chicago, IL, ²Rheumatology Associates S.C., Chicago, IL
Background/Purpose: Patients with fibromyalgia may feel depressed. But is it a clinical depression, suggesting the need for SSRI, SNRI, or other medication, or is it…
Abstract Number: 163 • 2017 ACR/ARHP Annual Meeting
Fibromyalgia Patients Identify More Causes of Disease Flare Ups Than RA Patients
Robert S. Katz¹, Lauren Kwan² and Jessica L. Polyak², ¹Rush University Medical Center, Chicago, IL, ²Rheumatology Associates S.C., Chicago, IL
Background/Purpose: We compared patients with the Fibromyalgia Syndrome (FMS) and Rheumatoid Arthritis (RA) patients with respect to stresses that the patients believe may have caused…
Abstract Number: 164 • 2017 ACR/ARHP Annual Meeting
Association of Natural Killer Cell Ligand Polymorphism, HLA-C Asn80Lys, with the Development of Anti-SSA/Ro Associated Congenital Heart Block
Hannah C. Ainsworth¹, Miranda C Marion¹, Antonio Brucato², Nathalie Costedoat-Chalumeau³, Tiziana Bertero⁴, Rolando Cimaz⁵, Micaela Fredi⁶, Patrick M. Gaffney⁷, Jennifer A. Kelly⁷, Kateri Levesque⁸, Alice Maltret⁸, Nathalie Morel⁸, Véronique Ramoni⁹, Amelia Ruffatti¹⁰, Carl D Langefeld¹, Jill P. Buyon¹¹ and Robert M Clancy¹¹, ¹Wake Forest University, Winston Salem, NC, ²Ospedale Papa Giovanni XXIII, Bergamo, Italy, ³Service de médecine interne Pôle médecine, Hôpital Cochin, Centre de référence maladies auto-immunes et systémiques rares de l’île de France, Paris, France, ⁴Ospedale Mauriziano, Torino, Italy, ⁵Department of Paediatrics, University of Florence and Anna Meyer Children's Hospital, Florence, Italy, Florence, Italy, ⁶Department of Rheumatology and Clinical Immunology, Rheumatology and Clinical Immunology, Rheumatology and Clinical Immunology, Spedali Civili of Brescia, Brescia, Italy, ⁷Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁸Université Paris Descartes-Sorbonne Paris Cité, Paris, France, ⁹Ospedale Papa Giovanni XXIII of Bergamo, Policlinico San Matteo of Pavia, Bergamo, Pavia, Italy, ¹⁰Unità di Reumatologia, Dipartimento di Medicina-DIMED, Università di Padova., Padova, Italy, ¹¹NYU Langone Medical Center, New York, NY
Background/Purpose: Fetal exposure to maternal anti-SSA/Ro antibodies is necessary but insufficient for the development of congenital heart block (CHB), suggesting the potential of a fetal…
Abstract Number: 165 • 2017 ACR/ARHP Annual Meeting
Rheumatoid Arthritis Risk Polymorphisms in CCR6, SNP and Estrogen-Dependent Response to Immune Mediator Gene Expression, and NF-κb Transcriptional Activity: Crosstalk between the Immune and Endocrine Systems
Ming-Fen Ho¹, Tim Bongartz², James N. Ingle³, Liewei Wang¹ and Richard M. Weinshilboum¹, ¹Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN, ²Emergency Medicine, Vanderbilt University, Nashville, TN, ³Department of Medical Oncology, Mayo Clinic, Rochester, MN
Background/Purpose: The rheumatoid arthritis (RA) risk locus CCR6 rs3093024 SNP is associated with increased risk of RA in a sex-specific pattern in Asian populations. Specifically,…
Abstract Number: 166 • 2017 ACR/ARHP Annual Meeting
Integrative Systems Biology Approach Identifies Key Transcription Factors and Novel Rheumatoid Arthritis (RA) and Individualized Therapeutic Targets
RIchard Ainsworth¹, Kai Zhang², Gary S. Firestein³ and Wei Wang⁴, ¹UC San Diego, La Jolla, CA, ²UCSD School of Engineering, San Diego, CA, ³Medicine, University of California San Diego, La Jolla, CA, ⁴Chemistry and Biochemistry, UC San Diego, La Jolla, CA
Background/Purpose: The search for novel targets in RA requires novel computational methods and in silicosystems to identify non-obvious pathways that account for the diversity of…
Abstract Number: 167 • 2017 ACR/ARHP Annual Meeting
Differentially Co-Expressed Gene Networks in Previously DMARD-Naïve Patients with Early RA Achieving Sustained Drug-Free Remission after Step-up Methotrexate Therapy
Xavier M Teitsma¹, Johannes WG Jacobs¹, Michal Mokry², Attila Pethö-Schramm³, Michelle EA Borm⁴, Jacob M. van Laar⁵, Johannes W.J. Bijlsma⁶ and Floris PJ Lafeber⁵, ¹Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ²Division of Pediatrics, University Medical Center Utrecht, Utrecht, Netherlands, ³F. Hoffmann-La Roche, Basel, Switzerland, ⁴Beneluxlaan 2a, Roche Nederland BV, Woerden, Netherlands, ⁵Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ⁶Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands
Background/Purpose: According to current standards, methotrexate (MTX) is an anchor drug in the treatment of rheumatoid arthritis (RA) and should be used in the initial…
Abstract Number: 168 • 2017 ACR/ARHP Annual Meeting
Identification of Novel Susceptibility Loci in a Large UK Cohort of Juvenile Idiopathic Arthritis (JIA) Cases
Samantha Smith¹, John Bowes¹, Joanna Cobb², Anne Hinks¹, Sunil Sampath¹, Annie Yarwood¹, Lucy R Wedderburn³, Kimme L. Hyrich⁴ and Wendy Thomson¹, ¹Arthritis Research UK Centre for Genetics and Genomics, Centre for Musculoskeletal Research, Manchester Academic Health Sciences Centre, The University of Manchester, Manchester, United Kingdom, ²NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester Academic Health Science Centre, Central Manchester Foundation Trust, Manchester, United Kingdom, ³3Arthritis Research UK Centre for Adolescent Rheumatology, UCL GOS Institute of Child Health, University College London, London, United Kingdom, ⁴Arthritis Research UK, Centre for Epidemiology, Centre for Musculoskeletal Research, Manchester Academic Health Sciences Centre, The University of Manchester, Manchester, United Kingdom
Background/Purpose: Juvenile idiopathic arthritis (JIA) is a group of chronic arthropathies of unknown cause affecting children under 16yrs, and is the most common childhood inflammatory…
Abstract Number: 169 • 2017 ACR/ARHP Annual Meeting
New Autoinflammatory Phenotype Associated with Homozygous AGBL3 Variant
Ahmet Gül¹, Neslihan Abaci² and Sema Sirma Ekmekci², ¹Department of Internal Medicine, Division of Rheumatology, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, ²Department of Genetics, Istanbul University Institute for Experimental Medical Research, Istanbul, Turkey
Background/Purpose: To identify new genes/pathways associated with autoinflammatory phenotype. Methods: We screened genomic variations by whole exome sequencing in 3 families presented with autoinflammatory findings…
Abstract Number: 170 • 2017 ACR/ARHP Annual Meeting
Genome-Wide Association Study of Clinically-Ascertained Gout and Subtypes Identifies Multiple Susceptibility Loci Including Transporter Genes
Hirotaka Matsuo¹, Akiyoshi Nakayama², Hirofumi Nakaoka³, Ken Yamamoto⁴, Masayuki Sakiyama⁵, Amara Shaukat⁶, Yu Toyoda⁷, Yukinori Okada⁸, Yoichiro Kamatani⁹, Masahiro Nakatochi¹⁰, Takahiro Nakamura⁵, Tappei Takada⁷, Hiroshi Nakashima⁵, Seiko Shimizu⁵, Makoto Kawaguchi⁵, Asahi Hishida¹¹, Kenji Wakai¹¹, Blanka Stiburkova¹², Karel Pavelka¹³, Lisa K. Stamp¹⁴, Nicola Dalbeth¹⁵, Tatsuo Hosoya¹⁶, Michiaki Kubo⁹, Hiroshi Ooyama¹⁷, Toru Shimizu¹⁸, Kimiyoshi Ichida¹⁹, Tony R. Merriman²⁰ and Nariyoshi Shinomiya²¹, ¹Department of Integrative Physiology and Bio-Nano Medicine, National Defense Medical College, Tokorozawa, Japan, ²Dept Integrative Physiol, National Defense Med College, Tokorozawa, Japan, ³National Inst Genet, Mishima, Japan, ⁴Department of Medical Chemistry, Kurume University School of Medicine, Kurume, Japan, ⁵National Defense Med College, Tokorozawa, Japan, ⁶Univ Otago, Dunedin, New Zealand, ⁷Univ Tokyo Hosp, Tokyo, Japan, ⁸Osaka University, Osaka, Japan, ⁹Center for Integrative Medical Sciences, RIKEN, Yokohama, Japan, ¹⁰Nagoya Univ Hosp, Nagoya, Japan, ¹¹Nagoya Univ Grad Sch Med, Nagoya, Japan, ¹²Institute of Inherited Metabolic Disorders, First Faculty of Medicine, Charles University, Prague, Czech Republic, ¹³Institute of Rheumatology, Prague, Czech Republic, ¹⁴University of Otago, Christchurch, New Zealand, ¹⁵University of Auckland, Auckland, New Zealand, ¹⁶Jikei Univ Sch Med, Tokyo, Japan, ¹⁷Ryougoku East Gate Clin, Tokyo, Japan, ¹⁸Kyoto Industr Health Assoc, Kyoto, Japan, ¹⁹Tokyo Univ Pharmacy Life Sci, Tokyo, Japan, ²⁰Biochemistry Dept, PO Box 56, University of Otago, Dunedin, New Zealand, ²¹National Defense Med College, Saitama, Japan
Background/Purpose: We performed a genome-wide association study (GWAS) of gout and its subtypes to identify novel gout loci including those that are subtype-specific. Methods: Putative…
Abstract Number: 171 • 2017 ACR/ARHP Annual Meeting
Finding Transcriptional Regulators Central to RA with Transcriptomics of IL17 Dose Response, Time Series, and siRNA Silencing in Stromal Cells
Kamil Slowikowski¹, Hung Nguyen², Gerald Watts², Fumitaka Mizoguchi³, Erika H. Noss⁴, Michael Brenner⁵ and Soumya Raychaudhuri⁶, ¹Harvard University, Boston, MA, ²Brigham and Women's Hospital, Boston, MA, ³Department of Rheumatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), Tokyo, Japan, ⁴Division of Rheumatology, University of Washington, Seattle, WA, ⁵Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁶Division of Medicine and Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Rheumatoid arthritis (RA) is characterized by immune cell infiltration into the synovial membrane of the joint, where they engage stromal cells such as synovial…
Abstract Number: 172 • 2017 ACR/ARHP Annual Meeting
Optimizing Precision Medicine By Using Genetics to Assign Diagnostic Prior Probabilities to Patients with Synovitis
Rachel Knevel^1,2,3,4, Chikashi Terao^5,6,7, Jing Cui^1,8, Kamil Slowikowski^2,9,10, TWJ Huizinga³, Elizabeth Karlson¹¹ and Soumya Raychaudhuri^1,2,12,13, ¹Division of Medicine and Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Medical and Population Genetics Program, Broad Institute of MIT and Harvard, Cambridge, MA, ³Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁴Division of Genetics, Brigham and Women's Hospital, Harvard Medical School, Bosten, MA, ⁵Laboratory for Statistical Analysis, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan, ⁶Clinical Research Center, Shizuoka General Hospital, Shizuoka, Japan, ⁷Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, Japan, ⁸Division of Genetics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁹Division of Medicine and Rheumatology, Brigham and Women's Hospital, Harvard Medical Schoo, Boston, MA, ¹⁰Division of Genetics, Brigham and Women's Hospital, Harvard Medical Schoo, Boston, MA, ¹¹Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ¹²Department of Institute of Inflammation and Repair, University of Manchester, Manchester, United Kingdom, ¹³Division of Genetics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: As the cost of genome-wide genotyping plummets, and biobanking efforts integrating medical records and genetics are rapidly expanding, many patients will have genotyping available…
Abstract Number: 173 • 2017 ACR/ARHP Annual Meeting
Applying Urine Proteomics for Discovery of Lupus Nephritis Damage Biomarkers in a Pediatric Cohort
Jessica Turnier¹, Bruce Aronow², Kenneth Greis³, Michael Bennett⁴, Wendy Haffey³, Sherry Thornton⁵, Gaurav Gulati⁶, Michael Wagner⁷, David Witte⁸, Prasad Devarajan⁹ and Hermine I. Brunner¹⁰, ¹Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Computational Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³University of Cincinnati College of Medicine, Cincinnati, OH, ⁴Nephrology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁵Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁶Division of Immunology, Allergy and Rheumatology, University of Cincinnati College of Medicine, Cincinnati, OH, ⁷Biomedical Informatics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁸Pathology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁹Nephrology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ¹⁰Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: Non-invasive biomarkers of lupus nephritis (LN) damage are needed to guide treatment decisions and determine risk for kidney failure. Urinary proteomics has advanced as…
Abstract Number: 174 • 2017 ACR/ARHP Annual Meeting
Transcriptional Profiling of Synovial Macrophages from RA Patients to Capture Disease Heterogeneity
Philip J. Homan¹, Arthur M. Mandelin II², Salina Dominguez¹, Emily Bacalao³, S. Louis Bridges Jr.⁴, Joan M. Bathon⁵, John Atkinson⁶, David Fox⁷, Eric L. Matteson⁸, Chris Buckley⁹, Costantino Pitzalis¹⁰, Deborah Parks¹¹, Laura Hughes¹², Laura Geraldino-Pardilla¹³, Robert Ike¹⁴, Kristine Phillips¹⁵, Kerry Wright¹⁶, Andrew Filer¹⁷, Stephen Kelly¹⁸, Eric M. Ruderman¹⁹, Carla Cuda¹, Hiam Abdala-Valencia³, Alexander Misharin³, G. R. Scott Budinger³, Richard M. Pope¹⁹, Harris Perlman²⁰ and Deborah R. WInter¹, ¹Department of Medicine Division of Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, ²Rheumatology, Northwestern University, Chicago, IL, ³Northwestern University, Chicago, IL, ⁴Clinical Immunology & Rheum, Univ of Alabama, Birmingham, AL, ⁵Division of Rheumatology, Columbia University Medical Center, New York, NY, ⁶Washington University in St. Louis, St. Louis, MO, ⁷Department of Medicine [Division of Rheumatology], University of Michigan Medical System, Ann Arbor, MI, ⁸Rheumatology, Mayo Clinic College of Medicine and Science, Rochester, MN, ⁹University of Birmingham, Birmingham, United Kingdom, ¹⁰Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Barts and The London, School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom, ¹¹Washington University School of Medicine in St. Louis, St. Louis, MO, ¹²University Alabama Birmingham, Birmingham, AL, ¹³Columbia University, New york, NY, ¹⁴Division of Rheumatology, University of Michigan, Ann Arbor, MI, ¹⁵University of Michigan, Ann Arbor, MI, ¹⁶Rheumatology, Mayo Clinic, Rochester, MN, ¹⁷Institute of Inflammation and Ageing (IIA), University of Birmingham, Birmingham, United Kingdom, ¹⁸William Harvey Research Institute, London, United Kingdom, ¹⁹Medicine/Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, ²⁰Department of Medicine, Division of Rheumatology, Northwestern University Feinberg School of Medicine, Northwestern University Feinberg School of Medicine,, Chicago, IL
Background/Purpose: In a given patient with rheumatoid arthritis (RA), it is difficult to predict disease progression or identify to which treatments they will respond. Macrophages…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].